Overview

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Status:
Active, not recruiting

Trial end date:
2021-12-21

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed (PSR) high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Olaparib